Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the
cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from
dividing so they stop growing or die. Combining thalidomide with chemotherapy may kill more
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of thalidomide, doxorubicin, and
dexamethasone in treating patients who have untreated stage II or stage III multiple myeloma.